Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Everardo Cobos

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
Journal of Oncology Practice|June 12, 2010
Practical model for psychosocial careSusan S Hendrick, Everardo Cobos
Texas Medicine|September 3, 2010
An update on hematological malignanciesNicholas C D'Cunha, Everardo Cobos
Anticancer Research|August 15, 2002
The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC)Cynthia Jumper, Everardo Cobos, Charles Lox
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 26, 2003
Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancerEverardo Cobos, Cynthia Jumper, Charles Lox
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|January 26, 2021
'Wisdom in the time of COVID-19'Everardo Cobos, Glenn Goldis, Richard McCallum
Respiratory Medicine|February 20, 2004
Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatmentCynthia Jumper, Everardo Cobos, Charles Lox
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 13, 2004
Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?Diana N Contreras, Everardo Cobos, Charles Lox
European Journal of Haematology|September 13, 2002
Acute myeloid leukaemia arising from a patient with untreated essential thrombocythaemiaJavier Bolaños-Meade, Carmen López-Arvizu, Everardo Cobos
International Reviews of Immunology|June 15, 2007
Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trialsMaurizio Chiriva-Internati, Everardo Cobos, W Martin Kast
International Reviews of Immunology|May 12, 2011
Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?Maurizio Chiriva-Internati, Everardo Cobos, Martin J Cannon
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
Journal of Oncology Practice|June 12, 2010
Practical model for psychosocial careSusan S Hendrick, Everardo Cobos
Texas Medicine|September 3, 2010
An update on hematological malignanciesNicholas C D'Cunha, Everardo Cobos
Anticancer Research|August 15, 2002
The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC)Cynthia Jumper, Everardo Cobos, Charles Lox
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 26, 2003
Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancerEverardo Cobos, Cynthia Jumper, Charles Lox
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|January 26, 2021
'Wisdom in the time of COVID-19'Everardo Cobos, Glenn Goldis, Richard McCallum
Respiratory Medicine|February 20, 2004
Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatmentCynthia Jumper, Everardo Cobos, Charles Lox
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 13, 2004
Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?Diana N Contreras, Everardo Cobos, Charles Lox
European Journal of Haematology|September 13, 2002
Acute myeloid leukaemia arising from a patient with untreated essential thrombocythaemiaJavier Bolaños-Meade, Carmen López-Arvizu, Everardo Cobos
International Reviews of Immunology|June 15, 2007
Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trialsMaurizio Chiriva-Internati, Everardo Cobos, W Martin Kast
International Reviews of Immunology|May 12, 2011
Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?Maurizio Chiriva-Internati, Everardo Cobos, Martin J Cannon
Pageof 12